Terazosin
Product Images NDC 33261-870

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 33261-870). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 1)

Formula (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 1)
Chemical structure of Terazosin, showing its molecular components including methoxy groups, nitrogen-containing rings, and a carbamate linked to a morpholine ring, with hydrochloride dihydrate indicated.*
FDA Label Image

Figure1 (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 2)

Figure1 (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 2)
Figure 1 presents two line graphs from Study 1 showing the effects of Terazosin versus placebo over three months. The left graph displays mean change in total symptom score from baseline, with Terazosin showing a greater decrease than placebo. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, where Terazosin demonstrates a larger increase compared to placebo. Sample sizes (N) and statistical significance markers are noted.*
FDA Label Image

Figure2 (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 3)

Figure2 (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 3)
A line graph titled 'Figure 2' showing the mean change in total symptom score from baseline over 30 months in a long-term, open-label, non-placebo controlled study with 494 participants. The vertical axis represents the mean change from baseline, and the horizontal axis shows time in months from 0 to 30. Data points show a decreasing trend in symptoms from month 0 to month 6, stabilizing thereafter with significant changes marked by asterisks.*
FDA Label Image

Figure3 (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 4)

Figure3 (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 4)
A line graph titled 'Mean Change in Peak Flow Rate from Baseline' showing data from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents time in months from 0 to 30, and the y-axis shows mean change from baseline in mL/sec ranging from 0.0 to 4.5. The graph depicts a generally increasing trend in peak flow rate change over time, with several points marked as statistically significant (p ≤ 0.05) compared to baseline, which had a mean value of 9.9 mL/sec.*
FDA Label Image

Image Label (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 5)

Image Label (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 5)
Terazosin 1 mg capsule label by Aidarex Pharmaceuticals LLC, showing a package size of 30 capsules. The label states each beige oblong capsule contains 1 mg terazosin hydrochloride. It includes the NDC 33261-0211-30, manufacturer's name Apotex Inc. Canada, and indicates the product is generic for Hytrin.*
FDA Label Image

Image Label (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 6)

Image Label (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 6)
Terazosin 2 mg capsules, packaged in a bottle containing 30 capsules. The label shows Aidarex Pharmaceuticals LLC as the distributor and Apotex Inc., Ontario Canada as the manufacturer. The label includes the active ingredient terazosin hydrochloride 2 mg per capsule and identifies the capsule as a yellow oblong with imprint APO 116 on one side. It is labeled as a generic for Hytrin with NDC 33261-0212-30.*
FDA Label Image

Image Label (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 7)

Image Label (Terazosin HCl 1mg 2mg 10mg Cap For Apotex 7)
Terazosin 10 mg oral capsules, 30 count, labeled by Aidarex Pharmaceuticals LLC. The label states the product contains terazosin hydrochloride 10 mg per capsule in blue oblong capsules marked with APO 118 on one side. Manufactured by Apotex Inc., Canada, this generic product is identified by NDC 33261-0870-30.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.